Day: September 7, 2023

Conductor Targets Beneath Layden Intrusive at Taylor Brook ProjectConductor Targets Beneath Layden Intrusive at Taylor Brook ProjectTORONTO, Sept. 07, 2023 (GLOBE NEWSWIRE) — Churchill Resources Inc. (“Churchill” or the “Company”) (TSXV: CRI) is pleased to announce results from its Hybrid Controlled Source Audio-Magnetotelluric (“Hybrid CSAMT”) survey carried out over the Layden Intrusive at Taylor Brook. The data suggests that multiple large conductor targets are present beneath Layden, hosted by similar and related magmatic rocks, below all drilling to date. Sizes of the conductor targets are significant, ranging up to several hundred metres long by >100m wide by >100m thick. Paul Sobie, CEO of Churchill stated, “The Hybrid CSAMT survey has proven successful at allowing us to see beneath Layden, and critically in identifying...

Infographic 1Infographic 1Infographic 2Infographic 2Infographic 3Infographic 3Infographic 4Infographic 4Infographic 5Infographic 5Drill Highlights:GD-23-197 drilled from Pad 16 intersected 3 sulphide-rich mineralized shear zones that include the Surebet Zone, Bonanza Shear and a new highly mineralized horizon within the Hazelton Volcanics located only 20 meters below the Bonanza Shear named the Golden Gate Zone, demonstrating the presence of at least 3 stacked and significantly mineralized shear zones outcropping that remain open. (see model and images below).A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4f49c03b-5cda-4077-9bba-f9c8b057d1a1The Golden Gate Zone is believed to be the fluid pathway proximal to the Surebet Zone...

Data presentations explore effects on patient-centric efficacy measures of treatments for patients with depression, and excessive sleepiness associated with obstructive sleep apnea and narcolepsy NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations of data from its CNS portfolio at the 2023 U.S. Psych Congress, being held in Nashville, Tenn. from September 6-10. The presentations demonstrate the Company’s commitment to continued innovation to address unmet needs in difficult-to-treat CNS disorders. “Axsome’s presentations at Psych Congress highlight our commitment to advancing research of medicines that have the potential to improve the...

Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placebo Study met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six months Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension Full study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT), met the primary endpoint. Zilebesiran demonstrated a clinically significant reduction in 24-hour mean systolic blood pressure (SBP) at month three,...

Oxford Biomedica to host webinar showcasing the TetraVectaTM system Oxford, UK – 07 September 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces that it will host a webinar on the TetraVectaTM system, the Company’s 4th generation lentiviral vector delivery system, on Monday 2 October 2023. The webinar titled “4th Generation Lentiviral Vectors: An Improved Gene Delivery System” will feature presentations by Dr Nick Clarkson, Vice President, Head of Platform Research at Oxford Biomedica and Dr Dan Farley, Senior Director of the Vector Engineering Group at Oxford Biomedica, who will discuss how the TetraVecta™ system can significantly enhance the development and manufacturing of safer and more effective lentiviral vector-based therapies through...

Dr. Alice Tomei of the University of Miami, Miller School of Medicine, to present updates in podium presentation at the 2023 IPITA-IXA-CTRMS Joint Congress being held in San Diego from October 26-29 LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 07, 2023 (GLOBE NEWSWIRE) — Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today provided a development update on its exclusively licensed, proprietary conformal coating immune protection technology, being advanced in combination with the Cell Pouch™ through a collaboration with Dr. Alice Tomei at the University of Miami, Miller School of Medicine. The goal of the technology is to eliminate the need for long-term use of conventional immunosuppressive medications currently required to prevent graft rejection with...

Higher lithium purity with lower leach temperature indicates enhanced economic potential VANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) — American Lithium Corp. (“American Lithium” or the “Company”) (TSX-V:LI | NASDAQ:AMLI | Frankfurt:5LA1) is pleased to announce results of on-going process work on TLC claystones aimed at continued improvement and optimization of all phases of the chemical process to produce lithium carbonate (“LC”). Optimization work focused on leaching conditions and lithium recovery, minimizing lithium losses during neutralization and magnesium sulphate crystallization, and on increasing the LC purity in the precipitation stage. Highlights:LC purity increased to 99.59% (up from 99.4%) Lower leach temperature of 50°C (down from 90°C), with continued high lithium extraction rates (95%); Significant...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 07, 2023 (GLOBE NEWSWIRE) — Evergold Corp. (TSX-V: EVER, OTC: EVGUF, WKN: A2PTHZ) (“Evergold” or the “Company”) is pleased to announce that it intends to complete a non-brokered private placement financing for aggregate gross proceeds of up to $1,500,000 through the issuance of a combination of flow-through units (“FT Units”) at a price of $0.06 per FT Unit and hard-dollar units of the Company (“HD Units”) at a price $0.055 per HD Unit (the “Offering”). It is expected that the majority of the gross proceeds from the sale of the FT Units will be used to support first-ever drilling of the newly optioned DEM Property (news, August 2, 2023), which hosts a large-scale copper-gold-silver porphyry target defined by multiple...

Fenn-Gib Canada’s first net-zero gold project Vision to develop Canada’s first net-zero gold mineVANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) —  Mayfair Gold Corp. (“Mayfair” or the “Company”) (TSX-V: MFG; OTCQB: MFGCF) today announced that Patrick Evans, president and CEO, will present at the 12th Annual Energy and Mines Toronto Summit. Mr. Evans will be presenting at 11 a.m. ET on November 29, 2023, on the topic “Displacing Diesel from Fleets: Miners’ Perspectives.” Commenting, Mr. Evans noted: “Climate change compels us to reimagine mining in Canada and globally. Gold is Canada’s most valuable mined commodity, valued in excess of $12 billion annually. The industry is a significant driver of economic activity across Canada, directly employing approximately 400,000 Canadians and offering the highest average...

Tigris patient enrollment momentum continues reaching 72 The Company anticipates three additional trial sites to be activated in Q3 NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 07, 2023 (GLOBE NEWSWIRE) — Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce that it has closed its previously announced ”bought deal” private placement of 9.0% convertible unsecured senior notes due November 1, 2026 (the “Notes“) of the Company at a price of US$1,000 per Note (the “Issue Price”) for aggregate gross proceeds of US$4,553,000 (the “Offering“). The Offering was conducted by Paradigm Capital Inc. (the “Underwriter”) and consisted of the sale of 4,553 Notes at a price of US$1,000 per Note. The Notes have a face value of US$1,000...